A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
Zhang H, Gu JM, Chao AJ, Cheng Q, Teng DH, Yu JM, Wang BW, Huo YN, Mao L, Zhang Q, Yang H, Yan SG, Zhang KQ, Zhao XL, Lin H, Pei Y, Yuan Z, Dai RC, He L, Chen L, Su YF, Deng ZL, You L, Ban B, Zhu M, Cao YL, Zhu YK, Li ZJ, Zhang Z, Yi CQ, Lu YB, Wang G, Han CC, Wang ZJ, Li XX, Zhang ZL.
Zhang H, et al. Among authors: lu yb.
Acta Pharmacol Sin. 2023 Feb;44(2):446-453. doi: 10.1038/s41401-022-00954-y. Epub 2022 Jul 27.
Acta Pharmacol Sin. 2023.
PMID: 35896694
Free PMC article.
Clinical Trial.